Takeda says its oral TYK2 inhibitor zasocitinib (TAK-279) demonstrated statistical superiority over Bristol Myers Squibb’s Sotyktu (deucravacitinib) in a Phase 3 head-to-head psoriasis readout from the Latitude Atlas program. The company highlighted efficacy across primary and secondary goals, reinforcing the competitive shift toward oral options in plaque psoriasis. The結果 adds pressure to the incumbency position of first-in-class TYK2 inhibition, while also sharpening differentiation within oral TYK2-class competitors as regulators and payers weigh longer-term durability and safety. Separately, the linked reporting emphasizes Takeda’s acquisition path for zasocitinib and its intent to capture a larger share of the oral-treated segment, which may influence future trial designs and combination strategies for moderate-to-severe psoriasis.